Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) last week said it closed the $166 million acquisition of ophthalmic and neurosurgical device maker Synergetics.
Valeant’s $6.50-per-share offer was a 48.1% premium over Synergetics stock’s closing price the day before the deal was announced last month.
The buyout includes $1 per share in milestones, with a 50¢-per-share bonus tied to an annual sales mark of $55 million in ophthalmic products by June 30, 2018, and another 50¢ per share tied to annual ophthalmic sales of $65 million by the same date, Synergetics said. The 2nd milestone would be pro-rated for sales between the 2 targets, according to the company.
“We are pleased to reach an agreement with Valeant, which is a logical partner to maximize our company’s growth opportunities and, importantly, this agreement creates immediate and compelling value for our shareholders,” president & CEO David Hable said when the merger was announced. “The combined strengths of both companies will expand the breadth of our offerings and create a more effective competitor that is better able to meet our customers’ needs in the ophthalmology and neurosurgery markets.”
Late last year Synergetics acquired a U.K.-based cannulae and needles maker Sterimedix for $13.5 million. In July Synergetics re-upped a supply deal with Stryker (NYSE:SYK).